Compare Eli Lilly And Co (LLY) vs Phillips 66 (PSX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Phillips 66 — how do they compare? Eli Lilly And Co trades at $1,159.99 (market cap $1.02T), while Phillips 66 trades at $211 (market cap $83.72B). The key difference: Eli Lilly And Co is far larger — about 12.2× Phillips 66's market cap, and Phillips 66 pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| LLY | PSX | |
|---|---|---|
Market Cap | $1.02T | $83.72B |
Sector | Health | Energy |
52-Week High | $1.24K | $208.80 |
52-Week Low | $625.65 | $118.37 |
Enterprise Value | $1.06T | $105.69B |
Dividend Yield | 0.6% | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.
Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.
PSX trades at $209.47, up 1.26% on the day, with strong technical momentum and bullish moving average signals. The stock benefits from elevated refining margins and has beaten earnings expectations in three consecutive quarters. Recent news highlights its advantage from tight fuel markets and Middle East supply dynamics, while the company maintains a solid dividend payout of $1.27 per share.
Outlook remains positive with 57% analyst buy ratings and a consensus price target of $201.50, though current price exceeds this. Risks include volatile oil prices and declining revenue trends from $170B in 2022 to $132.4B in 2025. Institutional sentiment is supported by efficient refining operations and strategic positioning in current energy markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
